INOmax® (inhaled nitric oxide) is indicated for the treatment of term and late pre-term (≥ 34 weeks) neonates with hypoxic respiratory failure associated with pulmonary hypertension.
Please consult the product monograph below for contraindications, warnings, precautions, adverse reactions, interactions, and conditions of clinical use. The product monograph is also available by calling us at 1-877-566-9466.
INOmax® DSIR Plus meets the criteria outlined in the INOmax® Product Monograph for delivery and monitoring of nitric oxide. The INOmax® DSIR Plus is provided as part of the INOmax® Total Care package with no capital outlay.
Users agree that access to and use of any website linked from this site and the content of either is at their own risk. Mallinckrodt Canada shall not be liable in any matter whatsoever for any direct, incidental, consequential, indirect or punitive damages arising from the access to, use of, or inability to use this website or any website linked to this site or for any errors or omissions in the content of either this website or any website linked to this site.